CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
推进癌症免疫治疗：从创新的临床前模型到临床见解
英文原题：Advancing cancer immunotherapy: from innovative preclinical models to clinical insights.
查看英文原题
Advancing cancer immunotherapy: from innovative preclinical models to clinical insights.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
癌症免疫学和免疫治疗的快速发展建立在早期免疫检查点抑制剂（ICI）和CAR-T 细胞在某些癌症类型中成功应用的基础之上。然而，在肿瘤微环境中免疫功能障碍的科学认识以及预测临床免疫治疗反应方面仍存在许多空白，以使更多癌症患者能够从免疫治疗中获益。Scientific Reports内的癌症免疫治疗专辑描述了针对这些概念的开创性临床前和临床研究，代表了该领域的重大见解和突破。
展开英文摘要原文
The rapid expansion of cancer immunology and immunotherapy builds upon the success of early immune checkpoint inhibitors (ICI) and chimeric antigen receptor T cells for some cancer types. Many gaps still exist, however, in the scientific knowledge of immune dysfunction in the tumour microenvironment and predicting clinical immunotherapy response to allow more cancer patients to benefit from immunotherapy.
The Cancer Immunotherapy Collection within Scientific Reports describes pioneering preclinical and clinical studies addressing these concepts, representing significant insights and breakthroughs in the field.
论文信息
- 作者
- Craig AW、Frieboes HB、Videira PA
- 第一作者单位
- Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. ac15@queensu.ca.Canada
- 通讯作者单位
- UCIBIO - Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, Universidade NOVA de Lisboa, Caparica, Portugal. p.videira@fct.unl.pt.Portugal
- 文献类型
- 社论
- 期刊
- Scientific reports2024 Jan 12
- 原文标识
- PubMed 38216668 · DOI 10.1038/s41598-024-51704-5
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →